Provectus Biopharmaceuticals Secures PV-10 Manufacturing Patent

Provectus pic

Provectus
Image: pvct.com

Possessing extensive executive experience in accounting and finance, Peter Culpepper serves as the chief operating officer and chief financial officer of Provectus Biopharmaceuticals. Recently, Peter Culpepper’s company announced the receipt of a United States patent that will extend protection to the manufacturing process of PV-10, a trial-stage drug that has been patented since 2013. The new patent prohibits the use of any alternative raw materials to create the same active ingredient found in PV-10.

With coverage until at least 2031, the new patent keeps the company’s intellectual property safe as it tests its proprietary drug through clinical trials, including a pivotal phase 3 trial examining the efficacy of PV-10 in the treatment of melanoma.

Co-inventors on the patent include scientists from Cambrex Charles City, a subsidiary of Cambrex Corporation. These scientists partnered with Provectus to develop the unique manufacturing process that makes it possible to produce the active ingredient in PV-10, and their inclusion on the patent is a small recognition of the contribution that they have made.

Advertisements

Provectus Biopharmaceuticals Begins PV-10 Metastatic Cancer Study

Provectus pic

Provectus
Image: pvct.com

An experienced accounting and finance executive, Peter Culpepper is the chief financial officer and chief operating officer of Provectus Biopharmaceuticals. Earlier this year, Peter Culpepper’s company announced that it would start a phase 1 study of the efficacy of PV-10 in the treatment of neuroendocrine tumors that have metastasized in the liver. The trial will involve 12 patients and will take place at the Queen Elizabeth Hospital in South Australia.

With the phase 1 study, the researchers hope to test the safety and tolerability, as well as the effectiveness, of PV-10 chemoablation. The study will run for two years, with interim data taken after a year. Participants are divided into two successive cohorts. The first will receive PV-10 treatment in a single liver tumor, while the second will receive treatment in multiple tumors.

To judge effectiveness of the treatment, research will assess the objective response rate of both treated and untreated tumors, as well as any changes in tumor biomarkers that might occur. The key biomarkers include 5-hydroxyindole acetic acid, chromogranin A, and somatostatin receptor expression.